Cannabis Stocks Rally as Rescheduling Momentum Builds on Wall Street
Multi-state operators and cannabis ETFs post double-digit gains as federal rescheduling prospects drive institutional interest and valuation resets across the sector.
Cannabis equities are experiencing their strongest rally in months as federal rescheduling developments trigger a sector-wide revaluation on Wall Street. Multi-state operators including Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) posted gains exceeding 15% in recent sessions, while the AdvisorShares Pure US Cannabis ETF (MSOS) surged to multi-month highs on heavy volume.
The momentum reflects growing institutional confidence that federal cannabis rescheduling from Schedule I to Schedule III will materialize within the current regulatory timeline. This shift would eliminate the punitive 280E tax provision that currently prevents cannabis companies from deducting standard business expenses, potentially boosting sector-wide EBITDA margins by 20-40 percentage points. For cash-flow positive operators like Green Thumb and Trulieve, the tax relief could translate to hundreds of millions in additional annual profits.
Wall Street analysts are rapidly updating price targets and coverage models to reflect the changing regulatory landscape. The sector's enterprise value-to-revenue multiples remain compressed compared to traditional consumer goods companies, creating significant upside potential if federal banking restrictions ease alongside rescheduling. Current valuations of 2-4x forward revenue for leading MSOs appear increasingly disconnected from their market positions and cash generation capabilities.
Institutional participation in cannabis equities has accelerated as regulatory risk diminishes and compliance frameworks solidify. Several major pension funds and endowments have quietly initiated positions in cannabis ETFs and leading operators, while investment banks expand their coverage universe beyond the current handful of analyst teams. This institutional adoption cycle typically precedes sustained sector outperformance in emerging industries.
The current rally builds on improving operational fundamentals across the cannabis sector, with leading MSOs reporting consecutive quarters of positive free cash flow and expanding market share in key states. As federal policy uncertainty decreases, cannabis companies are transitioning from regulatory arbitrage plays to traditional growth stories, attracting a broader investor base and supporting higher valuation multiples going forward.